Sun Pharma’s SPARC Signs a Research Collaboration with HitGen to Develop Therapies

 Sun Pharma’s SPARC Signs a Research Collaboration with HitGen to Develop Therapies

Sun Pharma’s SPARC Signs a Research Collaboration with HitGen to Develop Therapies

Shots:

  • HitGen to receive upfront & milestones and will utilize its DNA-encoded library design technology to develop therapies for Sun Pharma’s SPARC targets
  • The focus of the collaboration is to combine the SPARC’s research expertise with HitGen’s DELs based screening technology to develop therapies for serious medical conditions 
  • HitGen’s DELs is a platform for small molecule drug discovery including 400B macrocyclic compounds developing biological targets. The company has also collaborated with other companies & foundations in North America, Europe, Asia & Africa to discover therapies & agrochemical solutions

Click here to read full press release/ article | Ref: HitGen | Image: Livemint

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post